GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Caution] hepatic endpoints need biopsy data, not an ALT screenshot — 25 comments in the full submission. View in context.
266
c/survodutide·submitted 14 days ago by u/cato_girard

[Caution] hepatic endpoints need biopsy data, not an ALT screenshot

Cautionbranch of 9 comments

Confession thread, sort of. I went from 1.0mg to 15mg much faster than I should have because the scale had stalled and I got impatient. The stall broke about 17 weeks later, at which point I had no way of knowing whether the dose increase did anything or whether it would have broken anyway. So now I have muscle…

Read the full submission and all 25 comments →

This branch

9 comments, started 13 days ago
u/rania_marchand18 points·13 days ago

The practical rule people converge on is 28 days at fridge temperature after first puncture, and that comes from the preservative, not the peptide.

replysharereportpermalink
u/incretin_ivyMOD8 points·12 days ago

Flair changed to match the content. Read the sidebar before posting next time and we are square.

replysharereportpermalink
u/cato_batista5 points·12 days ago

the safety profile is not just tirzepatide amplified

replysharereportpermalink
u/kaia_cabrera2 points·12 days ago

MASH claims need the trial and the biopsy endpoint

replysharereportpermalink
u/border_paperwork3 points·12 days ago

the safety profile is not just tirzepatide amplified

Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.

replysharereportpermalink
load more comments (3) →
u/cato_girard12 points·12 days ago

The practical rule people converge on is 28 days at fridge temperature after first puncture, and that comes from the preservative, not the peptide.

Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.

replysharereportpermalink

← back to the whole thread

About c/survodutide

Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.

12kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/survodutide rules
  1. Glucagon co-agonism has a distinct safety story. Do not generalise from tirzepatide.
  2. MASH claims need the trial and the biopsy endpoint.
  3. Not approved. Descriptive posts only.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.